$TWST

Cho Dennis sold $1.8M of TWST

Cho Dennis (See Remarks) sold 9,514 shares of Twist Bioscience Corp (TWST) at $188.88 ($1.80M total) on 2026-10-02.

Original reporting
SEC EDGAR · Cho Dennis
Published Oct 5, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishMed
01

Why it matters

The disclosed sale provides fresh, material information that may influence short‑term trading decisions.

02

Market read

Insider sell of $1.8M is a primary disclosure that could generate modest bearish sentiment for TWST.

03

What to watch

No 10b5‑1 plan; the timing may reflect personal financial needs rather than company outlook.

Relevance 6/10Novelty 6/10Timing: post‑filing today

Background

SEC Form 4 filings disclose insider transactions; a sale by an officer is publicly reported and can affect investor perception.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

Officer Cho Dennis sold 9,514 shares of Twist Bioscience for $1.8M, reducing his stake to 63,789 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $1.8M open‑market sale by an officer is material but not large enough to trigger a major move; traders may watch for short‑term price weakness.

Market effects

May prompt scrutiny of insider activity in the biotech sector.

Limited to U.S. markets where TWST trades.

Low; impact confined to Twist Bioscience shareholders.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Twist Bioscience Corp

    Biotech company listed on NASDAQ under ticker TWST.

  • Cho Dennis

    Officer at Twist Bioscience who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.